However, OTUD1 conferred erlotinib susceptibility in NSCLC by repressing the nuclear translocation of YAP1 (112).OTUD5 knockdown also potentiated resistance to doxorubicin and cisplatin in NSCLC cells (113). The gene discussed is OTUD5; the disease is non-small cell lung carcinoma.